aadibio.com (AADI) Company Sales Revenue

Aadi Bioscience (AADI) sales figures demonstrate the impact of catalysts such as orphan drug status and the expanded application of Fyarro. However, liquidity shortages and the reduction of several studies are weighing on quotes, making the 0.03 mark a key metric. Revenue stability is supported by optimized international distribution of oncology drugs, which ensures high margins and preserves the therapeutic properties of the products.

AADI Aadi Bioscience Inc Revenue and Sales Volume (07/04/2022 - 03/19/2025)

Comprehensive metric breakdowns and analytics for Aadi Bioscience Inc (AADI)

- price and consensus price forecast:

Stock Price Aadi Bio|AADI - Price Target Chart

- market capitalization details:

Market Value Aadi Bioscience, Inc.|AADI - Enterprise Value

- balance sheet net asset value indicators:

Book Value of One Share Aadi Bioscience|AADI - Book Capitalization|Market-to-Book Ratio aadibio.com|AADI - Cumulative Company Assets

- debt and solvency information:

- earnings and multiples data:

AADI - Net Profit|Expected Net Income Aadi Bioscience|AADI - P/E Multiple|Projected Price to Earnings Ratio Aadi Bio|AADI - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Aadi Bioscience, Inc.|AADI - Operating profit EBITDA|Net earnings per share (EPS TTM) Aadi Bioscience|AADI - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months aadibio.com|AADI - Net earnings per share growth this year|Expected net earnings per share growth next year Aadi Bioscience

- company sales and revenue statistics:

AADI - Revenue and Sales Volume|Projected Sales Volume Aadi Bio|AADI - P/S Multiple|Forward P/S Multiple Aadi Bioscience, Inc.

Summary company analysis:aadibio.com AADI

Finished products of Aadi Bioscience, Inc.

This indicator tracks the daily cash inflow from product sales, allowing for an assessment of the business's commercialization pace and the accuracy of financial plan execution. An analysis of Aadi Bioscience (AADI) sales volume confirms the effective monetization of Fyarro for the treatment of sarcoma, where current revenues cover R&D costs and establish a foundation for further pipeline development.

Competing companies